Cargando…

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer

Phenotypic characterization of γδ T cells in the MALs (malignant ascites lymphocytes), TILs (tumor infiltrating lymphocytes), and PBLs (peripheral blood lymphocytes) of ovarian cancer (OvCA) patients is lacking. Therefore, we quantified γδ T cell prevalence in MAL, TIL, and PBL specimens from n = 18...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weimer, Pauline, Wellbrock, Jasmin, Sturmheit, Tabea, Oliveira-Ferrer, Leticia, Ding, Yi, Menzel, Stephan, Witt, Marius, Hell, Louisa, Schmalfeldt, Barbara, Bokemeyer, Carsten, Fiedler, Walter, Brauneck, Franziska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946192/ https://www.ncbi.nlm.nih.gov/pubmed/35326415 http://dx.doi.org/10.3390/cells11060964

Ejemplares similares

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
por: Brauneck, Franziska, et al.
Publicado: (2023)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
por: Wellbrock, Jasmin, et al.
Publicado: (2021)

Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML
por: Brauneck, F., et al.
Publicado: (2021)

Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia
por: Freisleben, Fabian, et al.
Publicado: (2021)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2020)

Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients
por: Jin, Zhenyi, et al.
Publicado: (2020)

TIM-3 and TIM-1 Could Regulate Decidual γδTCR Bright T Cells during Murine Pregnancy
por: Nörenberg, Jasper, et al.
Publicado: (2019)

Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2013)

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
por: Takamatsu, Kimiharu, et al.
Publicado: (2021)

Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice
por: Zhang, Yiwei, et al.
Publicado: (2019)

Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia
por: Freisleben, Fabian, et al.
Publicado: (2020)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
por: Yu, Lihua, et al.
Publicado: (2021)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
por: Gonçalves Silva, Isabel, et al.
Publicado: (2017)

PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells
por: Edwards, Sarah C., et al.
Publicado: (2022)

Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma
por: Xie, Xiaolin, et al.
Publicado: (2023)

Acute Myeloid Leukemia and the Bone Marrow Niche—Take a Closer Look
por: Behrmann, Lena, et al.
Publicado: (2018)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
por: Huang, Shuxin, et al.
Publicado: (2022)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
por: Jin, Shengming, et al.
Publicado: (2023)

The Clinical Significance of CD73 in Cancer
por: Bach, Niklas, et al.
Publicado: (2023)

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia
por: Latuske, Emily-Marie, et al.
Publicado: (2017)

Establishment and validation of an in vitro co-culture model for oral cell lines using human PBMC-derived osteoclasts, osteoblasts, fibroblasts and keratinocytes
por: Steller, Daniel, et al.
Publicado: (2020)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
por: Blessin, Niclas C., et al.
Publicado: (2019)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
por: Mollavelioglu, Baran, et al.
Publicado: (2022)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia
por: Velthaus, Arne, et al.
Publicado: (2019)

Decreased Frequency of Intestinal CD39(+) γδ(+) T Cells With Tissue-Resident Memory Phenotype in Inflammatory Bowel Disease
por: Libera, Jana, et al.
Publicado: (2020)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fm53ge171uq660kajhbkruqo73